Tag: GABA-B agonist / phenyl-GABA

  • Phenibut

    GABA-B agonist / phenyl-GABA

    A Soviet-developed phenyl-substituted GABA analog with GABA-B receptor agonism, used clinically in Russia for anxiety and sleep with documented dependence liability.

    Abstract

    Phenibut (4-amino-3-phenyl-butanoic acid; CAS 1078-21-3; molecular formula C10H13NO2; molecular weight 179.22) is a phenyl-substituted GABA analog developed in the Soviet Union in the 1960s at the Herzen State Pedagogical University. The phenyl substitution at the 3-position confers blood-brain barrier permeability that GABA itself lacks. Phenibut is approved in Russia, Belarus, Kazakhstan, and Latvia as Phenibut, Noofen, and Anvifen for anxiety, insomnia, asthenia, and post-traumatic stress disorder. Mechanism is primarily GABA-B receptor agonism (similar to baclofen) with secondary effects on voltage-gated calcium channels at higher doses. The (R)-enantiomer is the active component. Pharmacokinetics: plasma half-life 5 to 6 hours; rapid oral absorption. Phenibut has documented dependence liability with chronic high-dose use; withdrawal syndrome includes anxiety, insomnia, tremor, and rebound symptoms. The compound is sold as a research chemical/dietary supplement in the United States though regulatory classification is increasingly restrictive in some states. Investigators should be aware of the dependence potential and avoid daily dosing schedules.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.